Product Description
ABBV-668 is an inhibitor of receptor-interacting protein kinase 1 (RIPK1) being investigated for the treatment of several immune-mediated diseases. (Sourced from: https://www.abbvie.com/our-science/pipeline/abbv-668.html)
Mechanisms of Action: RIPK1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, France, Poland, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Colitis, Ulcerative
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| M21-446 | P2 |
Completed |
Colitis, Ulcerative |
2024-12-23 |
12% |
2025-01-09 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| M21-446 | P2 |
Completed |
Colitis, Ulcerative |
2024-12-05 |
12% |
2025-05-02 |
Treatments |
| M25-176 | P1 |
Completed |
Healthy Volunteers |
2024-09-20 |
50% |
2024-10-09 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
Recent News Events
Date |
Type |
Title |
|---|